AU6887096A - Immune direction therapy - Google Patents
Immune direction therapyInfo
- Publication number
- AU6887096A AU6887096A AU68870/96A AU6887096A AU6887096A AU 6887096 A AU6887096 A AU 6887096A AU 68870/96 A AU68870/96 A AU 68870/96A AU 6887096 A AU6887096 A AU 6887096A AU 6887096 A AU6887096 A AU 6887096A
- Authority
- AU
- Australia
- Prior art keywords
- immune
- therapy
- immune direction
- direction therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2518096P | 1996-09-11 | 1996-09-11 | |
US60025180 | 1996-09-11 | ||
PCT/IB1996/000945 WO1998010792A1 (fr) | 1996-09-11 | 1996-09-13 | Therapie a but immunitaire |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6887096A true AU6887096A (en) | 1998-04-02 |
Family
ID=21824510
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU68870/96A Abandoned AU6887096A (en) | 1996-09-11 | 1996-09-13 | Immune direction therapy |
AU41320/97A Abandoned AU4132097A (en) | 1996-09-11 | 1997-09-10 | Immune direction therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU41320/97A Abandoned AU4132097A (en) | 1996-09-11 | 1997-09-10 | Immune direction therapy |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0929568A2 (fr) |
JP (1) | JP2001503613A (fr) |
CN (1) | CN1230195A (fr) |
AU (2) | AU6887096A (fr) |
CA (1) | CA2265885A1 (fr) |
IL (1) | IL128806A0 (fr) |
NZ (1) | NZ335039A (fr) |
SE (1) | SE9900812L (fr) |
WO (2) | WO1998010792A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5297299A (en) * | 1998-08-17 | 2000-03-06 | Patrick T. Prendergast | Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use |
WO2000035472A2 (fr) * | 1998-12-15 | 2000-06-22 | Hollis-Eden Pharmaceuticals, Inc. | Cytokinotherapie combinee |
EP1265634A4 (fr) * | 2000-03-14 | 2005-12-28 | Nat Jewish Med & Res Center | Procede et composition pour traiter une hyperreactivite bronchique |
FI118263B (fi) * | 2002-10-09 | 2007-09-14 | Timo Kalevi Korpela | Kaspaasiaktiivisuutta säätelevät peptidit |
WO2005116081A2 (fr) | 2004-05-24 | 2005-12-08 | Genvault Corporation | Stockage proteique stable et stockage d'acides nucleiques stable sous forme recuperable |
EA008925B1 (ru) * | 2004-12-14 | 2007-08-31 | Товарищество С Ограниченной Ответственностью "Реал Мед Компани" | Способ коррекции иммунного состояния организма при сахарном диабете |
US7989590B2 (en) * | 2005-03-22 | 2011-08-02 | Rohto Pharmaceutical Co., Ltd | Peptides that increase collagen or hyaluronic acid production |
US7553932B1 (en) | 2005-04-25 | 2009-06-30 | La Jolla Institute For Allergy And Immunology | Methods of treating viral infection with IL-10 receptor antagonists |
US8932829B2 (en) | 2005-07-07 | 2015-01-13 | Elena Dudich | Recombinant alpha-fetoprotein and compositions thereof |
US8283165B2 (en) | 2008-09-12 | 2012-10-09 | Genvault Corporation | Matrices and media for storage and stabilization of biomolecules |
US9850278B2 (en) | 2013-04-25 | 2017-12-26 | Carmel-Haifa University Economic Corp. | Synthetic anti-inflammatory peptides and use thereof |
CN103275222B (zh) * | 2013-05-15 | 2014-04-16 | 中山康方生物医药有限公司 | 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用 |
CN114163493B (zh) * | 2021-11-18 | 2023-09-15 | 浙大宁波理工学院 | 一种可作为5型磷酸二酯酶抑制剂的多肽及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0056249B1 (fr) * | 1981-01-09 | 1985-06-26 | New York Blood Center, Inc. | Composition synthétique d'antigènes et leur procédé de préparation |
US4822606A (en) * | 1986-04-07 | 1989-04-18 | Duke University | Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences |
AU1366088A (en) * | 1987-01-28 | 1988-08-24 | Ortho Pharmaceutical Corporation | Immunosuppressive peptides and methods of use |
AU620804B2 (en) * | 1987-03-23 | 1992-02-27 | Hiver Limited | Novel vaccines |
SE8705197D0 (sv) * | 1987-12-30 | 1987-12-30 | Jonas Blomberg | New peptides, two diagnostic methods using the peptides and a medicament based on the peptides |
IL97629A0 (en) * | 1990-03-26 | 1992-06-21 | Schering Corp | Bcrf1 antagonists for treating epstein-barr virus infections |
WO1993011157A1 (fr) * | 1991-11-27 | 1993-06-10 | The Council Of The Queensland Institute Of Medical Research | VACCIN ET PEPTIDES CONTRE LA MALARIA COMPRENANT UN EPITOPE DE CELLULE T HUMAINE DE PROTEINE CIRCUMSPOROZOITE DE $i(P.VIVAX) |
ZA931489B (en) * | 1992-03-04 | 1993-10-28 | Schering Corp | Use of interleuken-10 to suppress graft-vs-host disease |
WO1993018783A1 (fr) * | 1992-03-20 | 1993-09-30 | Schering Corporation | Utilisation d'interleukine 10 pour induire la production d'antagoniste des recepteurs de l'interleukine 1 |
CA2144648A1 (fr) * | 1992-09-18 | 1994-03-31 | Mario Clerici | Retablissement de l'immunocompetence des cellules t auxiliaires chez les sujets infectes par le vih |
NZ269766A (en) * | 1993-07-28 | 1998-01-26 | Medvet Science Pty Ltd | Haemopoietic growth factor antagonists; relates to modified forms of such factors |
DE69536065D1 (de) * | 1994-01-14 | 2010-05-27 | Rath Matthias | Hydrophile Signal-Oligopeptide und Verfahren der therapeutischen Anwendung |
AU4385696A (en) * | 1996-01-18 | 1997-08-11 | Christian Gronhoj Larsen | Synthetic il-10 analogues |
-
1996
- 1996-09-13 AU AU68870/96A patent/AU6887096A/en not_active Abandoned
- 1996-09-13 WO PCT/IB1996/000945 patent/WO1998010792A1/fr active Application Filing
-
1997
- 1997-09-10 IL IL12880697A patent/IL128806A0/xx unknown
- 1997-09-10 WO PCT/IB1997/001086 patent/WO1998010787A2/fr not_active Application Discontinuation
- 1997-09-10 JP JP51343598A patent/JP2001503613A/ja active Pending
- 1997-09-10 NZ NZ335039A patent/NZ335039A/en unknown
- 1997-09-10 EP EP97939105A patent/EP0929568A2/fr not_active Withdrawn
- 1997-09-10 CA CA002265885A patent/CA2265885A1/fr not_active Abandoned
- 1997-09-10 AU AU41320/97A patent/AU4132097A/en not_active Abandoned
- 1997-09-10 CN CN97197816A patent/CN1230195A/zh active Pending
-
1999
- 1999-03-08 SE SE9900812A patent/SE9900812L/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0929568A2 (fr) | 1999-07-21 |
AU4132097A (en) | 1998-04-02 |
NZ335039A (en) | 2001-04-27 |
SE9900812D0 (sv) | 1999-03-08 |
WO1998010787A3 (fr) | 1998-07-30 |
CN1230195A (zh) | 1999-09-29 |
JP2001503613A (ja) | 2001-03-21 |
IL128806A0 (en) | 2000-01-31 |
WO1998010792A1 (fr) | 1998-03-19 |
WO1998010787A2 (fr) | 1998-03-19 |
SE9900812L (sv) | 1999-03-08 |
CA2265885A1 (fr) | 1998-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AUPO203996A0 (en) | Therapeutic uses | |
AU5457096A (en) | Gene-transfer-mediated angiogenesis therapy | |
AU4781297A (en) | Vaccines | |
AU2845197A (en) | Cycloalkano-pyridines | |
AU4370697A (en) | Coordination system | |
AU2684197A (en) | Handleset | |
AU4132097A (en) | Immune direction therapy | |
AU2090897A (en) | Hydroxyhexahydropyridazines | |
AUPO434196A0 (en) | An improved therapeutic | |
AU5119296A (en) | Magnetotherapy unit | |
AU2892995A (en) | Authentication technique | |
AU2547895A (en) | Therapeutic phenoxyalkylheterocycles | |
AU2237197A (en) | Fishing-lure | |
AU1900097A (en) | Cremators | |
AU1597197A (en) | Thienoquinolines | |
AU1740197A (en) | Vaccine against hantavirus | |
AU1289695A (en) | Human stanniocalcin-alpha | |
AU1643797A (en) | Repeater-system | |
AU4502797A (en) | Immunological therapy for cancer | |
AU7767894A (en) | Nutritory induction system | |
AU1205497A (en) | Vaccine component | |
AU3978697A (en) | Plasmin-depletion therapy | |
AUPO181796A0 (en) | Therapeutic uses | |
AU1255895A (en) | Human mutt2 | |
AU1445197A (en) | 3-methylimidazopyridines |